Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.70 |
| ▸ | PAX8 | Q06710 | 3/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | P4HB | P07237 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20634038 | 0.86 | KMT2A (0.67) | KMT2APAX8HSD11B1LMNAALDH1A1 | |
| SCHEMBL20633923 | 0.85 | KMT2A (0.65) | KMT2APAX8HSD11B1LMNAALDH1A1 | |
| SCHEMBL25128778 | 0.84 | KMT2A (0.76) | KMT2APAX8HSD11B1LMNAALDH1A1 | |
| SCHEMBL1951415 | 0.84 | KMT2A (0.76) | KMT2APAX8HSD11B1LMNAALDH1A1 | |
| SCHEMBL20633959 | 0.83 | KMT2A (0.62) | KMT2APAX8HSD11B1LMNAALDH1A1 | |
| SCHEMBL28825174 | 0.82 | KMT2A (1.00) | KMT2APAX8HSD11B1LMNAALDH1A1 | |
| SCHEMBL4617628 | 0.82 | KMT2A (0.74) | KMT2APAX8HSD11B1LMNAALDH1A1 | |
| SCHEMBL28825135 | 0.82 | KMT2A (1.00) | KMT2APAX8HSD11B1LMNAALDH1A1 | |
| SCHEMBL29275318 | 0.82 | HSD11B1 (0.78) | KMT2APAX8RAB9AHSD11B1LMNA | |
| SCHEMBL12264849 | 0.80 | KMT2A (0.70) | KMT2APAX8HSD11B1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | INTOCELL, INC. (KR) | 2023-11-07 | — | — | US | disclosed |
| US-11753431-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2023-09-12 | — | — | US | disclosed |
| US-20220162190-A1 | BENZODIAZEPINE DERIVATIVES AND USES THEREOF | INTOCELL, INC. (KR) | 2022-05-26 | — | — | US | disclosed |
| US-20220118104-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KR) | 2022-04-21 | — | — | US | disclosed |
| US-20220009946-A1 | FUSED HETEROCYCLIC BENZODIAZEPINE DERIVATIVES AND USES THEREOF | INTOCELL, INC. (KR) | 2022-01-13 | — | — | US | disclosed |
| US-20210393795-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KR) | 2021-12-23 | — | — | US | disclosed |
| US-20210388017-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KP) | 2021-12-16 | — | — | US | disclosed |
| US-11084801-B2 | Benzodiazepine derivatives and uses thereof | INTOCELL, INC. (KR) | 2021-08-10 | — | — | US | disclosed |
| US-11065343-B2 | Compound bearing beta-galactoside-introduced self-immolative linker | INTOCELL INC. (KR) | 2021-07-20 | — | — | US | disclosed |
| WO-2020141459-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KR) | 2020-07-09 | — | — | WO | disclosed |
| WO-2020141460-A2 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KR) | 2020-07-09 | — | — | WO | disclosed |
| US-20190328902-A1 | Compound Bearing Beta-Galactoside-Introduced Self-Immolative Linker | INTOCELL INC. (KR) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220118104-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | VIP, ANTXR2, TNFRSF9 | KMT2A 3544/4885PAX8 2311/4885RAB9A 4261/4885 |
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | GABRB3, GABRB2, GABRB1 | KMT2A 1869/4885PAX8 2812/4885RAB9A 3425/4885 |
| US-20220162190-A1 | BENZODIAZEPINE DERIVATIVES AND USES THEREOF | GABRB3, GABRB2, GABRB1 | KMT2A 1869/4885PAX8 2812/4885RAB9A 3425/4885 |
| US-20220009946-A1 | FUSED HETEROCYCLIC BENZODIAZEPINE DERIVATIVES AND USES THEREOF | GABRB2, GABRB3, GABRB1 | KMT2A 1898/4885PAX8 3346/4885RAB9A 2548/4885 |
| US-11065343-B2 | Compound bearing beta-galactoside-introduced self-immolative linker | DDOST, B3GAT3, GALNT10 | KMT2A 4590/4885PAX8 2587/4885RAB9A 3559/4885 |
| US-20190328902-A1 | Compound Bearing Beta-Galactoside-Introduced Self-Immolative Linker | DDOST, B3GAT3, GALNT10 | KMT2A 4590/4885PAX8 2587/4885RAB9A 3559/4885 |
| US-20210388017-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | VIP, ANTXR2, TNFRSF9 | KMT2A 3544/4885PAX8 2311/4885RAB9A 4261/4885 |
| US-11753431-B2 | Compounds comprising cleavable linker and uses thereof | VIP, ANTXR2, TNFRSF9 | KMT2A 3544/4885PAX8 2311/4885RAB9A 4261/4885 |
| US-11084801-B2 | Benzodiazepine derivatives and uses thereof | GABRB3, GABRB2, GABRB1 | KMT2A 1869/4885PAX8 2812/4885RAB9A 3425/4885 |
| US-20210393795-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | ANTXR2, VIP, TNFRSF9 | KMT2A 4471/4885PAX8 3591/4885RAB9A 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.